‹ Screener

Centessa Pharmaceuticals plc

CNTA · Pharmaceutical Preparations · 154.7M shares · +525%/yr ↑ dilution · EDGAR filings ↗

Reference price $30.12 · est. market cap ~$4.7B — last insider sale, 2026-03-26 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D46

Clinical/early-stage biotech — clinical-stage biopharma, heavy burn ($194M), well-funded.

Strengths

Risks

Notable findings

Quarterly revenue

2025-06-30 · $02025-09-30 · $02025-12-31 · $02026-03-31 · $0

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
-1384.6%
Net margin
-1316.9%
Return on equity
-37.5%
Return on assets
-28.7%
ROIC
-25.8%
Debt / equity
0.2×
Current ratio
8.6×
Free cash flow
-$194M
EBITDA
-$207M
Tangible book value
$527M
Cash & investments
$295M
Cash runway
6q
Stock comp / revenue
206.4%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-06-24INDEX VENTURES LIFE VI (JERSEY) L.P.Sell149K
2026-06-24HUSSAIN IQBAL JDisposition118K
2026-06-24HUSSAIN IQBAL JDisposition5.5K
2026-06-24Bush Tia LDisposition148K
2026-06-24Crowley John JDisposition45K
2026-06-24Anderson Karen M.Disposition62K
2026-06-24Deferiere RaphaelDisposition11K
2026-06-24Kanes StephenDisposition120K
2026-06-24Accardi Mario AlbertoDisposition243K
2026-06-24De Rubertis FrancescoDisposition4.4M
2026-06-24De Rubertis FrancescoDisposition56K
2026-06-24De Rubertis FrancescoDisposition3.9M
2026-06-24De Rubertis FrancescoDisposition94K
2026-06-24De Rubertis FrancescoDisposition11.2M
2026-06-24De Rubertis FrancescoDisposition281K
2026-06-24GOYAL ARJUNDisposition463K
2026-06-24Weinhoff Gregory MDisposition66K
2026-06-24Medicxi Ventures Management (Jersey) LtdSell4.4M
2026-06-24Medicxi Ventures Management (Jersey) LtdSell56K
2026-06-24Medicxi Ventures Management (Jersey) LtdSell3.9M
2026-06-24Medicxi Ventures Management (Jersey) LtdSell94K
2026-06-24Medicxi Ventures Management (Jersey) LtdSell11.2M
2026-06-24Medicxi Ventures Management (Jersey) LtdSell281K
2026-06-24INDEX VENTURES LIFE VI (JERSEY) L.P.Sell9.8M
2026-05-01Accardi Mario AlbertoTax withheld604$39.42
2026-03-26Weinhoff Gregory MOption exercise24K$3.85
2026-03-26Anderson Karen M.Option exercise41K$8.01
2026-03-26Anderson Karen M.Sell41K$30.12
2026-03-26Weinhoff Gregory MSell24K$30.00
2026-03-17Anderson Karen M.Option exercise10K$4.01
2026-03-17Anderson Karen M.Sell10K$28.10
2026-03-16Anderson Karen M.Sell65K$28.21
2026-03-16Anderson Karen M.Option exercise65K$4.01
2026-03-13Anderson Karen M.Sell12K$27.13
2026-03-13Anderson Karen M.Option exercise94K$4.01
2026-03-13Anderson Karen M.Option exercise15K$3.85
2026-03-13Anderson Karen M.Sell108K$26.15
2026-03-13Anderson Karen M.Option exercise109K$4.01
2026-03-13Anderson Karen M.Sell108K$26.15
2026-03-13Anderson Karen M.Sell12K$27.13
2026-03-13Weinhoff Gregory MSell61K$26.17
2026-03-13Weinhoff Gregory MSell12K$27.16
2026-02-02Bush Tia LGrant35K
2026-02-02Kanes StephenGrant120K
2026-02-02Crowley John JGrant45K
2026-02-02Deferiere RaphaelGrant11K
2026-02-02HUSSAIN IQBAL JSell39K$25.15
2026-02-02HUSSAIN IQBAL JGrant40K
2026-02-02HUSSAIN IQBAL JGrant20K
2026-02-02Weinhoff Gregory MGrant31K
2026-02-02Accardi Mario AlbertoGrant68K
2026-02-02Anderson Karen M.Grant29K
2026-02-01HUSSAIN IQBAL JTax withheld7.8K$24.57
2026-02-01Anderson Karen M.Tax withheld11K$24.57
2026-02-01Accardi Mario AlbertoTax withheld2.9K$24.57
2026-02-01Bush Tia LTax withheld8.5K$24.57
2026-02-01Weinhoff Gregory MTax withheld14K$24.57
2026-01-30HUSSAIN IQBAL JSell1.0K$25.01
2025-12-09Accardi Mario AlbertoSell7.4K$28.70
2025-12-09Accardi Mario AlbertoSell2.6K$29.21
2025-12-08Accardi Mario AlbertoOption exercise5.0K$9.53
2025-12-08Accardi Mario AlbertoSell10K$30.00
2025-11-17Bush Tia LOption exercise40K$9.42
2025-11-17HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-11-17HUSSAIN IQBAL JSell6.0K$27.64
2025-11-17Bush Tia LSell40K$28.00
2025-11-12Bush Tia LSell40K$26.00
2025-11-12Bush Tia LOption exercise40K$9.42
2025-11-01Accardi Mario AlbertoTax withheld593$24.90
2025-10-27Accardi Mario AlbertoSell8.0K$25.00
2025-10-27Accardi Mario AlbertoOption exercise5.0K$8.01
2025-10-15HUSSAIN IQBAL JSell6.0K$22.41
2025-10-15HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-09-24Bush Tia LOption exercise35K$9.42
2025-09-24Bush Tia LSell35K$24.00
2025-09-16Accardi Mario AlbertoSell7.4K$21.33
2025-09-16Accardi Mario AlbertoSell742$22.02
2025-09-15HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-09-15HUSSAIN IQBAL JSell6.0K$21.85
2025-09-10Bush Tia LSell25K$22.00
2025-09-10HUSSAIN IQBAL JOption exercise20K$5.84
2025-09-10HUSSAIN IQBAL JSell20K$22.00
2025-09-10Bush Tia LOption exercise25K$9.42
2025-09-09Accardi Mario AlbertoOption exercise5.0K$8.01
2025-09-09Bush Tia LOption exercise25K$8.01
2025-09-09Bush Tia LSell25K$20.00
2025-09-09HUSSAIN IQBAL JOption exercise20K$5.84
2025-09-09HUSSAIN IQBAL JSell20K$20.01
2025-09-09Accardi Mario AlbertoSell7.0K$20.00
2025-08-15HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-08-15HUSSAIN IQBAL JSell6.0K$17.23
2025-08-01Accardi Mario AlbertoTax withheld597$17.17
2025-07-29Accardi Mario AlbertoSell8.3K$15.23
2025-07-25Weinhoff Gregory MOption exercise10K$3.85
2025-07-25Weinhoff Gregory MSell10K$15.56
2025-07-21SAHA SAURABHSell55K$15.92
2025-07-21SAHA SAURABHOption exercise55K$3.85
2025-07-15HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-07-15HUSSAIN IQBAL JSell6.0K$14.93
2025-06-25Weinhoff Gregory MSell10K$13.86
2025-06-25Weinhoff Gregory MOption exercise10K$3.85
2025-06-24Accardi Mario AlbertoOption exercise15K$3.85
2025-06-24HUSSAIN IQBAL JOption exercise12K$5.84
2025-06-24HUSSAIN IQBAL JSell12K$14.02
2025-06-24Accardi Mario AlbertoSell15K$14.00
2025-06-20SAHA SAURABHOption exercise55K$3.85
2025-06-20SAHA SAURABHSell55K$12.63
2025-05-27Weinhoff Gregory MOption exercise10K$3.85
2025-05-27Weinhoff Gregory MSell10K$12.82
2025-05-20SAHA SAURABHOption exercise55K$3.85
2025-05-20SAHA SAURABHSell55K$12.71
2025-05-16GOYAL ARJUNBuy418K$12.73
2025-05-15GOYAL ARJUNBuy45K$12.24
2025-05-01HUSSAIN IQBAL JOption exercise311$5.84
2025-05-01HUSSAIN IQBAL JSell311$14.00
2025-04-28HUSSAIN IQBAL JSell2.1K$14.01
2025-04-28HUSSAIN IQBAL JOption exercise2.1K$5.84
2025-04-25HUSSAIN IQBAL JOption exercise3.6K$5.84
2025-04-25HUSSAIN IQBAL JSell3.6K$14.00
2025-04-25Weinhoff Gregory MSell12K$13.61
2025-04-22SAHA SAURABHSell40K$12.43
2025-04-21SAHA SAURABHSell15K$12.29
2025-03-25Weinhoff Gregory MOption exercise10K$3.85
2025-03-25Weinhoff Gregory MSell10K$16.34
2025-03-20SAHA SAURABHSell55K$16.69
2025-03-17HUSSAIN IQBAL JSell6.0K$16.45
2025-03-17CHAO DAVID MOption exercise3.5K$3.85
2025-03-17CHAO DAVID MSell5.5K$17.08
2025-03-17CHAO DAVID MSell1.5K$17.50
2025-03-17HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-02-25Weinhoff Gregory MSell11K$15.25
2025-02-20SAHA SAURABHSell54K$15.92
2025-02-20SAHA SAURABHSell775$16.54
2025-02-18HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-02-18HUSSAIN IQBAL JSell4.6K$15.91
2025-02-18HUSSAIN IQBAL JSell1.4K$17.05
2025-02-10Anderson Karen M.Option exercise429$4.01
2025-02-10Anderson Karen M.Sell429$18.99
2025-02-07Anderson Karen M.Option exercise31K$4.01
2025-02-07Anderson Karen M.Sell31K$19.03
2025-02-03Bush Tia LSell11K$16.86
2025-02-03Anderson Karen M.Sell6.5K$16.86
2025-02-01HUSSAIN IQBAL JTax withheld13K$16.92
2025-02-01Weinhoff Gregory MTax withheld14K$16.92
2025-02-01Bush Tia LTax withheld8.7K$16.92
2025-02-01CHAO DAVID MTax withheld13K$16.92
2025-02-01SAHA SAURABHTax withheld43K$16.92
2025-02-01Anderson Karen M.Tax withheld11K$16.92
2025-01-27Weinhoff Gregory MSell12K$16.47
2025-01-21SAHA SAURABHSell53K$15.76
2025-01-21SAHA SAURABHSell1.6K$16.19
2025-01-15HUSSAIN IQBAL JOption exercise6.0K$5.84
2025-01-15HUSSAIN IQBAL JSell6.0K$15.29

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT07598708 ↗A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1, Narcolepsy Type 2
PHASE2/PHASE3Recruiting2027-09-30
NCT06752668 ↗A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Narcolepsy Type 1, Narcolepsy Type 2
PHASE2Recruiting2026-12-01
NCT05821777 ↗A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
PHASE1/PHASE2Terminated2025-01-24

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-06-241.02Acquisition/dispositionDelisting notice3.035.01Exec/director changeOtherExhibitsfiling ↗
2026-06-12Shareholder voteOtherfiling ↗
2026-05-22Otherfiling ↗
2026-03-31Material agreementReg FDExhibitsfiling ↗
2026-02-13Exec/director changefiling ↗
2026-01-07Exec/director changeExhibitsfiling ↗
2025-12-11Exec/director changeReg FDExhibitsfiling ↗
2025-11-24OtherExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-242026-06-240001193125-26-280337 ↗
8-K2026-06-122026-06-120001193125-26-269474 ↗
8-K2026-05-222026-05-210001193125-26-236933 ↗
10-Q2026-05-052026-03-310001847903-26-000049 ↗
10-K2026-03-312025-12-310001847903-26-000025 ↗
8-K2026-03-312026-03-310001193125-26-134656 ↗
8-K2026-02-132026-02-090001193125-26-051424 ↗
8-K/A2026-01-072025-12-050001193125-26-004896 ↗
8-K2025-12-112025-12-050001193125-25-315074 ↗
8-K2025-11-242025-11-240001193125-25-292015 ↗
8-K2025-11-132025-11-110001193125-25-278827 ↗
8-K2025-11-052025-11-050001847903-25-000154 ↗